Actively Recruiting

Phase 2
Age: 18Years - 80Years
All Genders
ID04789044

A Phase 2a Multicenter Randomized Controlled Trial Evaluating the Safety and Efficacy of Polyethylene Glycol (PEG) Mediated Fusion (PEG Fusion) Compared to Standard of Care in the Repair of Mixed Motor-sensory Acute Peripheral Nerve Injuries (PNI) for Rapid and Immediate Improvement in Outcome

Led by Major Extremity Trauma Research Consortium · Updated on 2026-02-27

40

Participants Needed

7

Research Sites

52 weeks

Total Duration

On this page

Sponsors

M

Major Extremity Trauma Research Consortium

Lead Sponsor

U

United States Department of Defense

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are investigating the safety and effects of polyethylene glycol (PEG) fusion in patients with acute upper extremity peripheral nerve injuries. This Phase 2a randomized controlled trial aims to compare PEG fusion combined with primary nerve repair or reconstruction to conventional nerve reconstruction. The study seeks to establish safety data and assess clinical outcomes such as recovery of sensory and motor function, range of motion, hand strength, disability, pain, and patient satisfaction over up to two years. The trial will enroll 40 patients who have sustained complete peripheral nerve injuries in the upper extremity within 48 hours. Participants will be randomly assigned to receive either PEG-mediated nerve reconstruction using NTX-001 applied topically via a surgical device or conventional nerve reconstruction without PEG. NTX-001 is used as an adjunct during nerve repair surgery to promote axonal membrane fusion. The study hypothesizes that PEG fusion will have comparable short-term complication rates and may lead to earlier and improved functional recovery compared to standard surgery. Participants will be monitored for complications within the first 30 days and followed for up to two years to evaluate nerve regeneration and functional outcomes. Assessments include sensory and motor function recovery, range of motion, hand strength, pain levels, disability, and treatment satisfaction. The trial involves regular clinical evaluations to track progress and safety, with data also compared to an external prospective study for validation. Total participation duration spans up to two years post-surgery.

CONDITIONS

Brief Title

Evaluating the Safety and Efficacy of Polyethylene Glycol (PEG) Mediated Fusion (PEG Fusion)

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Ages 18 to 80 years
  • Sustained a complete peripheral nerve injury from upper extremity trauma within 48 hours
  • Injury involves motor and/or sensory function of axillary, radial, median, ulnar, or musculocutaneous nerves between the proximal humerus and wrist crease
  • Injury involves a mixed nerve segment containing both sensory and motor axons
Not Eligible

You will not qualify if you...

  • Surgery beginning within hours after injury
  • Injury to brachial plexus nerves
  • Injury distal to the wrist crease
  • Injury involving sensory-only distal nerve extensions or specific motor branches distal to the forearm midpoint
  • Previous peripheral nerve injury from trauma, stroke, or neurologic disorders
  • Documented psychiatric disorder likely to cause self-harm or interfere with follow-up
  • Severe problems maintaining follow-up (e.g., prisoners, homeless without support)
  • Not expected to survive 30 days due to injuries or health
  • Known allergy to polyethylene glycol (PEG)
  • Inability to perform required assessments on the contralateral side or abnormal baseline sensory values
  • Pregnant or breastfeeding
  • Significant medical conditions preventing immediate repair
  • Inability to adhere strictly to the clinical protocol

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Treatment

Duration - Surgery within 24 hours of injury

Participants receive either PEG mediated nerve reconstruction using NTX-001 applied topically during surgery or conventional nerve reconstruction.

1 surgical visit (in-person)

Follow-up

Duration - Up to 2 years

Participants are monitored for complications within the first 30 days and for nerve regeneration and functional recovery over 2 years.

Multiple follow-up visits over 2 years

Trial Site Locations

Total: 7 locations

1

University of Maryland Medical Center Shock Trauma Center

Baltimore, Maryland, United States, 21201

Actively Recruiting

2

Johns Hopkins University School of Medicine

Baltimore, Maryland, United States, 21213

Actively Recruiting

3

Cooper Health

Camden, New Jersey, United States, 08103

Actively Recruiting

4

OrthoCarolina

Charlotte, North Carolina, United States, 28207

Actively Recruiting

5

Wellspan Health

York, Pennsylvania, United States, 17403

Actively Recruiting

6

San Antonio Military Medical Center (SAMMC)

San Antonio, Texas, United States, 78234

Actively Recruiting

7

Virginia Commonwealth University Medical Center

Richmond, Virginia, United States, 23219

Actively Recruiting

Loading map...

Research Team

E

Elizabeth Wysocki, MA

A

Ala Elhelali, PhD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

A Comparison of NeuroSpan Bridge, NeuraGen Nerve Guide, and ...

Peripheral Nerve Injuries

Actively Recruiting

6 locations

Continuous Observational Monitoring Program for Allay123 Hy...

Peripheral Nerve Injuries

Actively Recruiting

2 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here